Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing.


Andrew C. von Eschenbach, M.D., currently serves as president of Samaritan Health Initiatives Inc. and as a senior fellow at the Milken Institute and the Bipartisan Policy Center.

Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)

Description

Company Information

Funding Insights

Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million)

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information